It will be interesting to see if TLR7/8 inhibitors (enpatoran, afimetoran and others) provide efficacy in SLE through inhibition of B-cell activation, reduction in IFN activity, or both as anifrolumab (anti-IFN receptor) has been found to be efficacious, but its impact on B-cells has not been well characterized (46). Here, TLR7 is linked to systemic lupus erythematosus.